Modeling oncogene addiction using RNA interference

被引:31
作者
Rothenberg, S. Michael [1 ,2 ,3 ]
Engelman, Jeffrey A. [1 ,3 ]
Le, Sheila [1 ]
Riese, David J., II [4 ]
Haber, Daniel A. [1 ,2 ,3 ]
Settleman, Jeffrey [1 ,3 ]
机构
[1] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA
[2] Howard Hughes Med Inst, Charlestown, MA 02129 USA
[3] Harvard Univ, Sch Med, Charlestown, MA 02129 USA
[4] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA
基金
美国国家卫生研究院;
关键词
EGF receptor; RNAi;
D O I
10.1073/pnas.0803217105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The clinical efficacy of selective kinase inhibitors suggests that some cancer cells may become dependent on a single oncogene for survival. RNAi has been increasingly used to understand such "oncogene addiction" and validate new therapeutic targets. However, RNAi approaches suffer from significant off-target effects that limit their utility. Here, we combine carefully titrated lentiviral-mediated short hairpin RNA knockdown of the epidermal growth factor receptor (EGFR) with heterologous reconstitution by EGFR mutants to rigorously analyze the structural features and signaling activities that determine addiction to the mutationally activated EGFR in human lung cancer cells. EGFR dependence is differentially rescued by distinct EGFR variants and oncogenic mutants, is critically dependent on its heterodimerization partner ErbB-3, and surprisingly, does not require autophosphorylation sites in the cytoplasmic domain. Quantitative "oncogene rescue" analysis allows mechanistic dissection of oncogene addiction, and, when broadly applied, may provide functional validation for potential therapeutic targets identified through large-scale RNAi screens.
引用
收藏
页码:12480 / 12484
页数:5
相关论文
共 28 条
[1]   Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].
Bell, DW ;
Lynch, TJ ;
Haserlat, SM ;
Harris, PL ;
Okimoto, RA ;
Brannigan, BW ;
Sgroi, DC ;
Muir, B ;
Riemenschneider, MJ ;
Iacona, RB ;
Krebs, AD ;
Johnson, DH ;
Giaccone, G ;
Herbst, RS ;
Manegold, C ;
Fukuoka, M ;
Kris, MG ;
Baselga, J ;
Ochs, JS ;
Haber, DA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092
[2]   Induction of an interferon response by RNAi vectors in mammalian cells [J].
Bridge, AJ ;
Pebernard, S ;
Ducraux, A ;
Nicoulaz, AL ;
Iggo, R .
NATURE GENETICS, 2003, 34 (03) :263-264
[3]   Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib [J].
Carey, Kendall D. ;
Garton, Andrew J. ;
Romero, Maria S. ;
Kahler, Jennifer ;
Thomson, Stuart ;
Ross, Sarajane ;
Park, Frances ;
Haley, John D. ;
Gibson, Neil ;
Sliwkowski, Mark X. .
CANCER RESEARCH, 2006, 66 (16) :8163-8171
[4]   Essential role for oncogenic Ras in tumour maintenance [J].
Chin, L ;
Tam, A ;
Pomerantz, J ;
Wong, M ;
Holash, J ;
Bardeesy, N ;
Shen, Q ;
O'Hagan, R ;
Pantginis, J ;
Zhou, H ;
Horner, JW ;
Cordon-Cardo, C ;
Yancopoulos, GD ;
DePinho, RA .
NATURE, 1999, 400 (6743) :468-472
[5]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[6]   Minimizing the risk of reporting false positives in large-scale RNAi screens [J].
Echeverri, Christophe J. ;
Beachy, Philip A. ;
Baum, Buzz ;
Boutros, Michael ;
Buchholz, Frank ;
Chanda, Sumit K. ;
Downward, Julian ;
Ellenberg, Jan ;
Fraser, Andrew G. ;
Hacohen, Nir ;
Hahn, William C. ;
Jackson, Aimee L. ;
Kiger, Amy ;
Linsley, Peter S. ;
Lum, Lawrence ;
Ma, Yong ;
Mathey-Prevot, Bernard ;
Root, David E. ;
Sabatini, David M. ;
Taipale, Jussi ;
Perrimon, Norbert ;
Bernards, Rene .
NATURE METHODS, 2006, 3 (10) :777-779
[7]   ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines [J].
Engelman, JA ;
Jänne, PA ;
Mermel, C ;
Pearlberg, J ;
Mukohara, T ;
Fleet, C ;
Cichowski, K ;
Johnson, BE ;
Cantley, LC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3788-3793
[8]   Reversible tumorigenesis by MYC in hematopoietic lineages [J].
Felsher, DW ;
Bishop, JM .
MOLECULAR CELL, 1999, 4 (02) :199-207
[9]   Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation [J].
Godin-Heymann, Nadia ;
Bryant, Ianthe ;
Rivera, Miguel N. ;
Ulkus, Lindsey ;
Bell, Daphne W. ;
Riese, David J. ;
Settleman, Jeffrey ;
Haber, Daniel A. .
CANCER RESEARCH, 2007, 67 (15) :7319-7326
[10]   Patterns of somatic mutation in human cancer genomes [J].
Greenman, Christopher ;
Stephens, Philip ;
Smith, Raffaella ;
Dalgliesh, Gillian L. ;
Hunter, Christopher ;
Bignell, Graham ;
Davies, Helen ;
Teague, Jon ;
Butler, Adam ;
Edkins, Sarah ;
O'Meara, Sarah ;
Vastrik, Imre ;
Schmidt, Esther E. ;
Avis, Tim ;
Barthorpe, Syd ;
Bhamra, Gurpreet ;
Buck, Gemma ;
Choudhury, Bhudipa ;
Clements, Jody ;
Cole, Jennifer ;
Dicks, Ed ;
Forbes, Simon ;
Gray, Kris ;
Halliday, Kelly ;
Harrison, Rachel ;
Hills, Katy ;
Hinton, Jon ;
Jenkinson, Andy ;
Jones, David ;
Menzies, Andy ;
Mironenko, Tatiana ;
Perry, Janet ;
Raine, Keiran ;
Richardson, Dave ;
Shepherd, Rebecca ;
Small, Alexandra ;
Tofts, Calli ;
Varian, Jennifer ;
Webb, Tony ;
West, Sofie ;
Widaa, Sara ;
Yates, Andy ;
Cahill, Daniel P. ;
Louis, David N. ;
Goldstraw, Peter ;
Nicholson, Andrew G. ;
Brasseur, Francis ;
Looijenga, Leendert ;
Weber, Barbara L. ;
Chiew, Yoke-Eng .
NATURE, 2007, 446 (7132) :153-158